Comparison of efficacy of oral Levamisole and Formoterol+Budesonide inhaler with standard treatment of Corona infection.

Phase 2

• Conditions: Corona virus infection.; COVID-19, confirmed by laboratory testing; U07.1

• Registration Number: IRCT20200324046852N1
• Lead Sponsor: Fasa University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

COVID-19 positive patients with positive, PCR and chest CT scan

Exclusion Criteria

Patients with sever respiratory problems including patients with:1. Spo2<60%2. Severe respiratory distress3. Heamodynamic instabilitty 4. Acid base disturbance 5. Severe Anemia
Patients with hepatic diseases
Patients with Nervous system diseases

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response to treatment in Lymphocytes count. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Response to treatment for COVID-19 specific PCR test. Timepoint: Days 0-3-7. Method of measurement: Using PCR apparatus.;Response to treatment in O2 level and CO2 level in ABG or VBG test. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Chest CT-Scan response to treatment including dispersion size of Ground Glass area, bronchitis and consolidation. Timepoint: Days 0-3-7. Method of measurement: CT scan apparatus.

Secondary Outcome Measures

Name	Time	Method
Blood pressure response to treatment. Timepoint: daily. Method of measurement: By Sphygmomanometer.;Creatinine level during intervention. Timepoint: Daily. Method of measurement: By apparatus in diagnostic labs.;Level of CRP ( C reactive protein) in response to intervention. Timepoint: Daily. Method of measurement: By apparatus in diagnostic labs.